<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Metersky, Mark L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibiotic Resistance: Treatment and Drug Development Challenges Addressed</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-29</style></pages><abstract><style  face="normal" font="default" size="100%">The resistance of infectious organisms to currently available antibiotics is a major medical challenge. The prevalence and mechanisms of multidrug-resistant pathogens vary widely worldwide. In the United States and Europe, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) appears to have stabilized, while it is increasing in other regions [Dantes R et al. JAMA Intern Med 2013]. Antibiotic resistance to gram-negative bacteria continues to increase and represents one of the biggest challenges.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>